JP2023524039A5 - - Google Patents

Info

Publication number
JP2023524039A5
JP2023524039A5 JP2022566066A JP2022566066A JP2023524039A5 JP 2023524039 A5 JP2023524039 A5 JP 2023524039A5 JP 2022566066 A JP2022566066 A JP 2022566066A JP 2022566066 A JP2022566066 A JP 2022566066A JP 2023524039 A5 JP2023524039 A5 JP 2023524039A5
Authority
JP
Japan
Prior art keywords
approximately
dose
compound
subject
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029539 external-priority patent/WO2021222342A1/en
Publication of JP2023524039A publication Critical patent/JP2023524039A/ja
Publication of JP2023524039A5 publication Critical patent/JP2023524039A5/ja
Pending legal-status Critical Current

Links

JP2022566066A 2020-04-29 2021-04-28 Ｔ型カルシウムチャネルモジュレーターを使用する方法 Pending JP2023524039A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063017140P 2020-04-29 2020-04-29
US63/017,140 2020-04-29
US202063050410P 2020-07-10 2020-07-10
US63/050,410 2020-07-10
US202063082946P 2020-09-24 2020-09-24
US63/082,946 2020-09-24
PCT/US2021/029539 WO2021222342A1 (en) 2020-04-29 2021-04-28 Methods of use of t-type calcium channel modulators

Publications (2)

Publication Number Publication Date
JP2023524039A JP2023524039A (ja) 2023-06-08
JP2023524039A5 true JP2023524039A5 (https=) 2024-05-09

Family

ID=78373913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566066A Pending JP2023524039A (ja) 2020-04-29 2021-04-28 Ｔ型カルシウムチャネルモジュレーターを使用する方法

Country Status (11)

Country Link
US (1) US20230165847A1 (https=)
EP (1) EP4142764A4 (https=)
JP (1) JP2023524039A (https=)
KR (1) KR20230018384A (https=)
CN (1) CN115776894A (https=)
AU (1) AU2021263804A1 (https=)
BR (1) BR112022021946A2 (https=)
CA (1) CA3177277A1 (https=)
IL (1) IL297642A (https=)
MX (1) MX2022013595A (https=)
WO (1) WO2021222342A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3996746A4 (en) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
US20250170114A1 (en) * 2022-02-03 2025-05-29 Praxis Precision Medicines, Inc. Methods of treatment using t-type calcium channel modulators
WO2023192885A2 (en) * 2022-03-28 2023-10-05 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators
AU2024229946A1 (en) * 2023-03-02 2025-09-11 Praxis Precision Medicines, Inc. Crystalline salts of a t-type calcium channel modulator and methods of use thereof
CN121127456A (zh) * 2023-03-02 2025-12-12 普拉西斯精密医药公司 N-((1-(2-(叔丁基氨基)-2-氧代乙基)哌啶-4-基)甲基)-3-氯-5-氟苯甲酰胺的结晶盐形式和其使用方法
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
DK3364993T3 (da) * 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
EP3340988B1 (en) * 2015-11-12 2025-04-09 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
MX388586B (es) * 2016-12-16 2025-03-20 Idorsia Pharmaceuticals Ltd Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t.
WO2018118101A1 (en) * 2016-12-21 2018-06-28 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
MY204493A (en) * 2017-11-10 2024-08-30 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disorders
TWI879741B (zh) * 2018-10-03 2025-04-11 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Similar Documents

Publication Publication Date Title
JP2023524039A5 (https=)
TWI335217B (en) Pharmaceutical formulations of modafinil
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2022522270A5 (https=)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2026035701A5 (https=)
JP2018507243A5 (https=)
JP2023535744A5 (https=)
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
JP2022521233A5 (https=)
US20230233496A1 (en) Levodopa fractionated dose composition and use
US5985933A (en) Methods for treating central and peripheral nerve pain
Grøn Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease
US8785469B2 (en) Method of treating atherogenic dyslipidemia
JP2022506019A (ja) 高用量の放出調節フペルジン製剤の使用
JP2024059812A5 (ja) 鏡像異性体的に濃縮された、または純粋なブプロピオンの組成物
JP2021530568A5 (https=)
JP2021509671A5 (https=)
JP2024502466A5 (https=)
US12161612B2 (en) Methods and compositions for reducing symptoms of Parkinson's disease
EP4694877A1 (en) Methods and compositions for reducing symptoms of parkinson's disease
RU2664693C1 (ru) Способ предоперационной подготовки пациентов к офтальмологическим операциям
JP2023507764A5 (https=)
NL8600137A (nl) Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten.